Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab
Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab
复制标题
DOI：
10.1136/annrheumdis-2017-212504
复制
发表时间：
2018-05-01
影响因子：
27.4
通讯作者：
Tummala, Raj
中科院分区：
文献类型：
--
作者：
Morand, Eric F.;Trasieva, Teodora;Tummala, Raj
目的在一项事后分析中，我们旨在验证狼疮低疾病活动状态（LLDAS）定义作为系统性红斑狼疮（SLE）IIb期随机对照试验（RCT）的终点（MUSE [NCT 01438489]），然后利用LLDAS来区分阿尼福鲁单抗和安慰剂。（300 mg，n=99; 1，000 mg，n=104）Q4 W+标准治疗48周。获得LLDAS（SLE疾病活动指数2000
Objectives In a post-hoc analysis, we aimed to validate the Lupus Low Disease Activity State (LLDAS) definition as an endpoint in an systemic lupus erythematosus (SLE) Phase IIb randomised controlled trial (RCT) (MUSE [NCT01438489]) and then utilize LLDAS to discriminate between anifrolumab and placebo.Methods Patients received intravenous placebo (n=102) or anifrolumab (300 mg, n=99; 1,000 mg, n=104) Q4W plus standard of care for 48 weeks. LLDAS attainment (SLE Disease Activity Index 2000